Royal Philips Electronics (Netherlands) and
Immunetrics Inc. (Pittsburgh) are teaming up to explore future-generation approaches to improve the treatment of infectious disease in critical care.
Under the joint development agreement, Philips Research and Immunetrics will investigate the combination of advanced bioinformatics and computer modeling to identify opportunities to reduce the incidence and improve the management of systemic infection, a major complicating factor among many critically ill patients, say the companies.
Philips currently owns a 29 percent stake in Immunetrics, a biosimulation company specializing in the computational modeling of pathophysiology and treatment.
